Sanofi Deprioritizes Four Assets, Including Mid-Stage Dwarfism Treatment

1. Sanofi Deprioritizes Four Assets: Sanofi has decided to deprioritize four assets, including a mid-stage treatment for a form of dwarfism and three early-stage studies.
2. Mid-Stage Dwarfism Candidate: The most advanced drug to be discontinued is an anti-FGFR3 antibody for achondroplasia, the most common type of dwarfism, which was in phase 2 trials.
3. Reason for Deprioritization: The exact reason for the deprioritization is not specified, but it is part of a broader rare disease clear-out by Sanofi.
4. Impact on Rare Disease Research: This decision may have implications for the development of treatments for rare diseases, including achondroplasia.